Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity

BACKGROUND. Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We previously reported that by increasing the daily tamoxifen dose to 40 mg/day in CYP2D6 intermediate metabolizer (IM), but not poor metabolizer (PM), patients achieve endoxifen concentration...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Hertz, Daniel L., Deal, Allison, Ibrahim, Joseph G., Walko, Christine M., Weck, Karen E., Anderson, Steven, Magrinat, Gustav, Olajide, Oludamilola, Moore, Susan, Raab, Rachel, Carrizosa, Daniel R., Corso, Steven, Schwartz, Garry, Graham, Mark, Peppercorn, Jeffrey M., Jones, David R., Desta, Zeruesenay, Flockhart, David A., Evans, James P., McLeod, Howard L., Carey, Lisa A., Irvin, William J.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2016
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943390/
https://ncbi.nlm.nih.gov/pubmed/27226358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0480
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados